We studied COVID-19 associated mucormycosis based on 17 cases reported nationwide and assessed the differences with India. They differed by frequencies of diabetes mellitus (47% in France versus up to 95% in India), hematological malignancies (35% versus 1%), anatomical sites (12% versus >80% rhino-orbito-cerebral) and prognosis (88% mortality versus <50%).
Keywords: CAM; CAPA; COVID-19; mucormycosis.
© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.